Effects of Rosuvastatin on the, in Vivo, Kinetic of apoB and apoA1, Using Stable Isotopes, in Type 2 Diabetic Patients
Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
Statins have been shown to reduce significantly the risk for cardiovascular events in
patients with type 2 diabetes and statin therapy is largely recommended in this high
cardiovascular risk population. However, a residual cardiovascular risk is observed in
patients with type 2 diabetes treated by statins. This may be due to the fact that statins do
not correct all lipid abnormalities associated with diabetic dyslipidaemia, such as hyperTG
and low HDL-cholesterol.
Rosuvastatin is a statin which, in addition to its efficacy to reduce LDL-cholesterol, has
been show to decrease significantly plasma triglycerides. However, the effects of
rosuvastatin on triglyceride rich lipoproteins and HDL remains unknown. The purpose of this
study is to analyze the effect rosuvastatin 20 mg on the metabolism of triglyceride rich
lipoproteins and HDL in patients with Type 2 diabetes using and in vivo kinetic study of
VLDL1-apoB,VLDL2-apoB,IDL-apoB and HDL-apoA1.